In 1992, Congress passed the Prescription Drug User Fee Act. The idea was simple on its surface: pharmaceutical companies would pay fees to the FDA to fund faster drug reviews. The agency was underfunded. The backlog was long. The industry was impatient. The deal was made.
What happened over the following thirty years is a masterclass in regulatory capture.
The Numbers
Today, more than half of the FDA's Center for Drug Evaluation and Research budget comes directly from pharmaceutical industry user fees. In fiscal year 2023, that figure was approximately $1.3 billion — paid by the very companies whose drug applications the agency reviews.
This is not a conspiracy. It is published in federal budget documents. It is the official funding architecture of the agency. The FDA is, in a very real and measurable sense, dependent on the pharmaceutical industry for its operational budget.
The Revolving Door
Between 2006 and 2019, more than half of FDA medical officers who approved cancer drugs and then left the agency went on to work for the pharmaceutical industry — often within a year of leaving. This is not an aberration. It is a career track.
The incentive structure is explicit: FDA reviewers who want to maximize their post-government earning potential have every reason to cultivate relationships with industry contacts, avoid adversarial stances, and build a reputation as a pragmatic regulator rather than a hard-line one. The revolving door doesn't require corruption. It requires rational career planning.
Accelerated Approval and the Surrogate Endpoint Problem
The FDA's accelerated approval pathway allows drugs to be approved based on surrogate endpoints — lab markers or imaging findings that are presumed to predict clinical benefit — rather than proven improvements in how patients feel, function, or survive. Once approved, companies are supposed to conduct confirmatory trials.
An analysis published in JAMA found that a significant portion of drugs granted accelerated approval either never completed their confirmatory trials within the expected window or had those trials extended without penalty. Drugs generating hundreds of millions in annual revenue remained on the market based on surrogate data while the confirmatory evidence was pending for years.
The agency that was supposed to be protecting patients from unproven drugs had become the mechanism for monetizing unproven drugs while the proof was pending.
What Regulatory Capture Actually Looks Like
Regulatory capture doesn't require bribery. It doesn't require a single smoking-gun memo. It operates through funding dependency, career incentives, advisory committee composition, and the slow normalization of industry-friendly interpretations of ambiguous standards.
The result is an agency that is procedurally independent but structurally compromised — one that can truthfully say it follows its own rules while those rules were shaped by the same industry the agency regulates.
This is how captured institutions work. The capture is in the architecture, not the conduct.